Published in

Elsevier, American Heart Journal, (172), p. 144-151

DOI: 10.1016/j.ahj.2015.11.004

Links

Tools

Export citation

Search in Google Scholar

Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF–TIMI 48) trial

Journal article published in 2016 by Alon Eisen, Robert P. Giugliano ORCID, Christian T. Ruff, Francesco Nordio, Harinder S. Gogia, Vivek R. Awasty, David A. Henderson, Michele F. Mercuri, Howard Rutman, Elliott M. Antman, Eugene Braunwald
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Edoxaban is a specific anti-Xa inhibitor that, in comparison to warfarin, has been found to be noninferior for the prevention of stroke or systemic embolism (SSE) and to reduce bleeding significantly in patients with nonvalvular atrial fibrillation (AF). The US Food and Drug Administration (FDA) approved the higher-dose edoxaban regimen (60/30 mg) in patients with AF and a creatinine clearance of ≤95 mL/min. We report for the first time the clinical characteristics, efficacy, and safety of the FDA-approved population in the ENGAGE AF–-TIMI 48 trial.